List of Figures
Figure 1: COPD Therapeutics Market, Treatment Algorithm of COPD 17
Figure 2: COPD Market, Global, Moderate-to-Severe COPD Marketed Products Heatmap, Efficacy and Safety, 2017 33
Figure 3: COPD Market, Global, Very Severe COPD Marketed Products Heatmap, Efficacy and Safety, 2017 34
Figure 4: COPD Therapeutics Market, Global, Pipeline, 2017 36
Figure 5: COPD Therapeutics Market, Global, Pipeline by Molecular Target, 2017 37
Figure 6: Pipeline for COPD Therapeutics by Molecular Target and Stage of Development, Global, 2017 39
Figure 7: COPD Therapeutics Market, APAC, Mepolizumab Market ($m), 2019–2023 41
Figure 8: COPD Therapeutics Market, APAC, Benralizumab Market ($m), 2020–2023 43
Figure 9: COPD Therapeutics Market, APAC, PT003 Market ($m), 2018–2023 44
Figure 10: COPD Therapeutics Market, APAC, PT010 Market ($m), 2019–2023 46
Figure 11: COPD Therapeutics Market, APAC, FF/UMEC/VI Market ($m), 2018–2023 47
Figure 12: COPD Therapeutics Market, APAC, CHF-5993 Market ($m), 2020–2023 49
Figure 13: COPD Market, Global, Pipeline Heatmap, Efficacy, 2017 49
Figure 14: COPD Therapeutics Market, Global, Competitor Matrix for Efficacy and Safety of Marketed and Pipeline Products, 2017 51
Figure 15: COPD Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006–2016 53
Figure 16: COPD Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006–2016 54
Figure 17: COPD Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006–2016 55
Figure 18: COPD Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2016 56
Figure 19: COPD Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006–2016 57
Figure 20: COPD Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006–2016 58
Figure 21: COPD Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006–2016 59
Figure 22: COPD Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006–2016 60
Figure 23: COPD Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006–2016 61
Figure 24: COPD Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 62
Figure 25: COPD Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 62
Figure 26: COPD Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2016–2023 64
Figure 27: COPD Therapeutics Market, India, Treatment Patterns (million), 2016–2023 65
Figure 28: COPD Therapeutics Market, India, Annual Cost of Therapy ($), 2016–2023 66
Figure 29: COPD Therapeutics Market, India, Market Size ($m), 2016–2023 67
Figure 30: COPD Therapeutics Market, China, Treatment Patterns (million), 2016–2023 68
Figure 31: COPD Therapeutics Market, China, Annual Cost of Therapy ($), 2016–2023 69
Figure 32: COPD Therapeutics Market, China, Market Size ($bn), 2016–2023 70
Figure 33: COPD Therapeutics Market, Australia, Treatment Patterns (million), 2016–2023 71
Figure 34: COPD Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016–2023 72
Figure 35: COPD Therapeutics Market, Australia, Market Size ($m), 2016–2023 73
Figure 36: COPD Therapeutics Market, South Korea, Treatment Patterns (million), 2016–2023 74
Figure 37: COPD Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016–2023 75
Figure 38: COPD Therapeutics Market, South Korea, Market Size ($m), 2016–2023 75
Figure 39: COPD Therapeutics Market, Japan, Treatment Patterns (million), 2016–2023 76
Figure 40: COPD Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016–2023 77
Figure 41: COPD Therapeutics Market, Japan, Market Size ($m), 2016–2023 78
Figure 42: COPD Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2017 81
Figure 43: COPD Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2017 82
Figure 44: COPD Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017 83
Figure 45: COPD Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2017 84
Figure 46: COPD Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006–2017 85
Figure 47: COPD Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006–2017 88
Figure 48: COPD Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2017 89
Figure 49: COPD Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017 90
Figure 50: COPD Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006–2017 91
Figure 51: COPD Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006–2017 92